JP2016514099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514099A5 JP2016514099A5 JP2015558975A JP2015558975A JP2016514099A5 JP 2016514099 A5 JP2016514099 A5 JP 2016514099A5 JP 2015558975 A JP2015558975 A JP 2015558975A JP 2015558975 A JP2015558975 A JP 2015558975A JP 2016514099 A5 JP2016514099 A5 JP 2016514099A5
- Authority
- JP
- Japan
- Prior art keywords
- nme7
- muc1
- cancer
- cells
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 60
- 102000004169 proteins and genes Human genes 0.000 claims 33
- 206010028980 Neoplasm Diseases 0.000 claims 29
- 210000004027 cell Anatomy 0.000 claims 29
- 201000011510 cancer Diseases 0.000 claims 28
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 27
- 102100034256 Mucin-1 Human genes 0.000 claims 27
- 108010033276 Peptide Fragments Proteins 0.000 claims 23
- 102000007079 Peptide Fragments Human genes 0.000 claims 23
- 101001128732 Homo sapiens Nucleoside diphosphate kinase 7 Proteins 0.000 claims 22
- 102100032115 Nucleoside diphosphate kinase 7 Human genes 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 16
- 241000124008 Mammalia Species 0.000 claims 15
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 claims 14
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 claims 14
- 238000000034 method Methods 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 101001128739 Homo sapiens Nucleoside diphosphate kinase 6 Proteins 0.000 claims 10
- 102100032113 Nucleoside diphosphate kinase 6 Human genes 0.000 claims 10
- 102000035160 transmembrane proteins Human genes 0.000 claims 10
- 108091005703 transmembrane proteins Proteins 0.000 claims 10
- 230000027455 binding Effects 0.000 claims 8
- 230000003993 interaction Effects 0.000 claims 8
- 239000000178 monomer Substances 0.000 claims 7
- 210000000130 stem cell Anatomy 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 230000003449 preventive effect Effects 0.000 claims 5
- 239000000539 dimer Substances 0.000 claims 4
- 210000004602 germ cell Anatomy 0.000 claims 4
- 239000013610 patient sample Substances 0.000 claims 4
- 210000001082 somatic cell Anatomy 0.000 claims 4
- 238000002255 vaccination Methods 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 3
- 210000000628 antibody-producing cell Anatomy 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 101100346929 Homo sapiens MUC1 gene Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 210000004748 cultured cell Anatomy 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 102000057860 human MUC1 Human genes 0.000 claims 2
- 229930014626 natural product Natural products 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000000381 tumorigenic effect Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767206P | 2013-02-20 | 2013-02-20 | |
| US61/767,206 | 2013-02-20 | ||
| US201361768992P | 2013-02-25 | 2013-02-25 | |
| US61/768,992 | 2013-02-25 | ||
| US201361774558P | 2013-03-07 | 2013-03-07 | |
| US61/774,558 | 2013-03-07 | ||
| US201361837560P | 2013-06-20 | 2013-06-20 | |
| US61/837,560 | 2013-06-20 | ||
| PCT/US2013/050563 WO2014012115A2 (en) | 2012-07-13 | 2013-07-15 | Method for inducing cells to less mature state |
| USPCT/US2013/050563 | 2013-07-15 | ||
| PCT/US2013/051899 WO2014018679A2 (en) | 2012-07-24 | 2013-07-24 | Nme variant species expression and suppression |
| USPCT/US2013/051899 | 2013-07-24 | ||
| US201361865092P | 2013-08-12 | 2013-08-12 | |
| US61/865,092 | 2013-08-12 | ||
| PCT/US2013/055015 WO2014028668A2 (en) | 2012-08-14 | 2013-08-14 | Stem cell enhancing therapeutics |
| USPCT/US2013/055015 | 2013-08-14 | ||
| US201361894365P | 2013-10-22 | 2013-10-22 | |
| US61/894,365 | 2013-10-22 | ||
| US201361901343P | 2013-11-07 | 2013-11-07 | |
| US61/901,343 | 2013-11-07 | ||
| US201461925190P | 2014-01-08 | 2014-01-08 | |
| US61/925,190 | 2014-01-08 | ||
| US201461925601P | 2014-01-09 | 2014-01-09 | |
| US61/925,601 | 2014-01-09 | ||
| US201461938051P | 2014-02-10 | 2014-02-10 | |
| US61/938,051 | 2014-02-10 | ||
| PCT/US2014/017515 WO2014130741A2 (en) | 2013-02-20 | 2014-02-20 | Nme inhibitors and methods of using nme inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019109262A Division JP6862497B2 (ja) | 2013-02-20 | 2019-06-12 | Ｎｍｅ阻害剤、及びｎｍｅ阻害剤を使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514099A JP2016514099A (ja) | 2016-05-19 |
| JP2016514099A5 true JP2016514099A5 (enExample) | 2017-03-16 |
| JP6577872B2 JP6577872B2 (ja) | 2019-09-18 |
Family
ID=51391971
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558975A Active JP6577872B2 (ja) | 2013-02-20 | 2014-02-20 | Ｎｍｅ阻害剤、及びｎｍｅ阻害剤を使用する方法 |
| JP2019109262A Active JP6862497B2 (ja) | 2013-02-20 | 2019-06-12 | Ｎｍｅ阻害剤、及びｎｍｅ阻害剤を使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019109262A Active JP6862497B2 (ja) | 2013-02-20 | 2019-06-12 | Ｎｍｅ阻害剤、及びｎｍｅ阻害剤を使用する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20150089677A1 (enExample) |
| EP (1) | EP2958940A4 (enExample) |
| JP (2) | JP6577872B2 (enExample) |
| KR (2) | KR20210082547A (enExample) |
| CN (1) | CN105229027A (enExample) |
| AU (2) | AU2014218872A1 (enExample) |
| CA (1) | CA2901893C (enExample) |
| IL (2) | IL307628A (enExample) |
| WO (1) | WO2014130741A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6640086B2 (ja) * | 2013-08-12 | 2020-02-05 | ミネルバ バイオテクノロジーズ コーポレーション | 腫瘍成長を増強する方法 |
| CA2945162A1 (en) * | 2014-04-07 | 2015-10-15 | Minerva Biotechnologies Corporation | Use of an anti-nme antibody for treatment or prevention of cancer |
| CN116199790A (zh) | 2015-02-10 | 2023-06-02 | 米纳瓦生物技术公司 | 人源化抗MUCl*抗体 |
| JP2018520682A (ja) * | 2015-07-01 | 2018-08-02 | ミネルバ バイオテクノロジーズ コーポレーション | 幹細胞に基づいた器官および組織生成の方法 |
| WO2017053886A2 (en) | 2015-09-23 | 2017-03-30 | Minerva Biotechnologies Corporation | Method of screening for agents for differentiating stem cells |
| WO2020163325A1 (en) | 2019-02-04 | 2020-08-13 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| US12049514B2 (en) | 2020-06-08 | 2024-07-30 | Minerva Biotechnologies Corporation | Anti-NME antibody and method of treating cancer or cancer metastasis |
| US20230242678A1 (en) * | 2020-06-26 | 2023-08-03 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| IL316221A (en) | 2022-04-12 | 2024-12-01 | Minerva Biotechnologies Corp | Anti-MUC1* variant antibodies and their uses |
| WO2023215235A2 (en) * | 2022-05-03 | 2023-11-09 | The Regents Of The University Of California | Peptide inhibitors for chromodomain helicase dna binding protein 4 (chd4) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6947298A (en) * | 1997-04-03 | 1998-10-22 | Joslin Diabetes Center Inc. | Modulating the rad-nm23 interaction |
| DE60236605D1 (de) * | 2001-09-05 | 2010-07-15 | Minerva Biotechnologies Corp | Zusammensetzungen und deren verwendung zur behandlung von krebs |
| CN101652469B (zh) * | 2006-12-06 | 2014-04-16 | 米纳瓦生物技术公司 | 用于鉴定和操作细胞的方法 |
| WO2009042814A1 (en) * | 2007-09-25 | 2009-04-02 | Minerva Biotechnologies Corp. | Early diagnosis and treatment of drug resistance in muc1-positive cancer |
| WO2009075817A1 (en) * | 2007-12-06 | 2009-06-18 | Minerva Biotechnologies Corporation | Method for treating cancer using interference rna |
| JP2012505636A (ja) * | 2008-10-09 | 2012-03-08 | ミネルバ バイオテクノロジーズ コーポレーション | 細胞において多能性を誘導する方法 |
| MX2011013385A (es) * | 2009-06-11 | 2012-05-29 | Minerva Biotechnologies Corp | Metodos para cultivar celulas madre y celulas progenitoras. |
| CN103068971B (zh) * | 2010-06-16 | 2021-08-31 | 米纳瓦生物技术公司 | 重编程癌细胞 |
| WO2012154759A2 (en) * | 2011-05-09 | 2012-11-15 | Minerva Biotechnologies Corporation | Genetically engineered growth factor variants |
-
2014
- 2014-02-20 WO PCT/US2014/017515 patent/WO2014130741A2/en not_active Ceased
- 2014-02-20 KR KR1020217019794A patent/KR20210082547A/ko not_active Ceased
- 2014-02-20 KR KR1020157026033A patent/KR20150121131A/ko not_active Ceased
- 2014-02-20 JP JP2015558975A patent/JP6577872B2/ja active Active
- 2014-02-20 CN CN201480022551.6A patent/CN105229027A/zh active Pending
- 2014-02-20 AU AU2014218872A patent/AU2014218872A1/en not_active Abandoned
- 2014-02-20 IL IL307628A patent/IL307628A/en unknown
- 2014-02-20 EP EP14753856.5A patent/EP2958940A4/en active Pending
- 2014-02-20 CA CA2901893A patent/CA2901893C/en active Active
- 2014-02-20 IL IL240695A patent/IL240695B2/en unknown
- 2014-08-25 US US14/468,106 patent/US20150089677A1/en not_active Abandoned
-
2019
- 2019-03-29 AU AU2019202199A patent/AU2019202199B2/en active Active
- 2019-06-12 JP JP2019109262A patent/JP6862497B2/ja active Active
-
2021
- 2021-05-03 US US17/306,477 patent/US20220089779A1/en not_active Abandoned
- 2021-10-04 US US17/449,932 patent/US20220193270A1/en active Pending
- 2021-12-10 US US17/548,312 patent/US20220218846A1/en not_active Abandoned
-
2024
- 2024-02-12 US US18/439,331 patent/US20240277803A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514099A5 (enExample) | ||
| JP7638360B2 (ja) | Ｃｄ４７によって媒介される食作用を操作するための方法 | |
| US12162950B2 (en) | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis | |
| Seyfrid et al. | CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment | |
| AU2017306038B2 (en) | Anti-KRAS-G12D T cell receptors | |
| TWI558411B (zh) | FOXM1 peptides and agents containing this peptide | |
| EA015534B1 (ru) | Антитела к миостатину и способы их применения | |
| JP2018500012A5 (enExample) | ||
| JP2016505635A (ja) | Ｍａｇｅ−ａ１を認識する高結合活性結合分子 | |
| JP2018070640A (ja) | 幹細胞増強治療法 | |
| Riccardo et al. | Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial | |
| EP4263611A1 (en) | Cea6 binding molecules and uses thereof | |
| JP2022028075A (ja) | 免疫寛容を誘導する抗体、誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤治療法 | |
| EP2909236B1 (en) | Methods and compositions for the treatment of pancreatic cancer | |
| CN114195882A (zh) | Tcr及其用途 | |
| BR112018075654B1 (pt) | Anticorpos monoclonais, composições farmacêuticas, linhagem celular de hibridoma, usos dos referidos anticorpos monoclonais e métodos para detectar a expressão de cdh1 | |
| US10047164B2 (en) | Methods and compositions for the treatment of pancreatic cancer | |
| JP2022109936A (ja) | キラー免疫グロブリン様受容体（ｋｉｒ）ファミリーのシグナル伝達を標的とするモノクローナル抗体 | |
| JP2024517986A (ja) | 抗－ＣＤ３００ｃ抗体を利用した併用療法 | |
| HK40055783A (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| WO2022133074A1 (en) | Muc1 binding molecules and uses thereof | |
| JP2020500877A (ja) | 骨髄異形成症候群の治療のための組成物および方法 |